Biomarker Discovery with Artificial Intelligence

Patent-pending technologies

Public biomarker data can be analyzed and combined with enterprise data to gain new insights. This is enabled by our patent-pending technologies that normalize and understand the language of life science.

AI-enabled algorithms

AI-enabled algorithms generate unbiased sets of hypotheses for potential biomarkers or combinations testing all possible scenarios.

Extensive biological validation

Extensive biological multigraph-based scientific validation over public knowledge is deployed to ensure high biomarker prediction accuracy while removing false positives.

Continuous intuitive interface

Continuous intuitive interface transparently visualizes interpretation of AI output with relevant network and provenances from public literature.

• Of all drugs approved by the FDA in 2017, 41% were associated with biomarkers, and the biomarker discovery market is still growing [IQVIA institute report. 2019]
• In contrast to other drugs in development, biomarkers focused on treating cancer have seen slow progress in the last 30 years [Diamandis EP, BMC Med. 2012]
• It is unacceptably easy to publish “statistically significant” evidence, which makes it hard to identify crucial results in research [Simmons et al, Psychol Sci. 2011]

Life sciences data, coupled with Innoplexus’s AI and data analytics solutions, can help researchers accurately pinpoint novel biomarkers. Our proprietary technology provides deep-dive insights to predict biomarker response in a disease model or along pathways.

Pharmaceutical companies

Increase the likelihood of regulatory approval by predicting biomarker response.

Medium biotechs

Stratify patient groups with relevant biomarkers for maximum returns.

CROs

Assess biomarkers to find the right ones for your clinical trials and improve the probability of success.